Effect of denosumab on glycolipids and cardiovascular indices in patients with postmenopausal osteoporosis
10.3969/j.issn.1673-9701.2024.14.018
- VernacularTitle:地舒单抗对绝经后骨质疏松症患者糖脂及心血管指标的影响
- Author:
Lufeng WANG
1
;
Kaidi ZHANG
;
Yanying GUO
Author Information
1. 石河子大学医学院,新疆石河子 832000;新疆维吾尔自治区人民医院内分泌与代谢病科 新疆糖尿病临床医学研究中心,新疆乌鲁木齐 830000
- Keywords:
Denosumab;
Osteoporosis;
Glucose metabolism;
Lipid metabolism;
Cardiovascular disease
- From:
China Modern Doctor
2024;62(14):79-83
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of denosumab on glucose-lipid metabolism and cardiovascular in patients with postmenopausal osteoporosis(POMP).Methods Patients diagnosed with POMP in Xinjiang Uygur Autonomous Region People's Hospital from 1 January 2017 to 31 August 2022 were selected,and the patients were divided into the desutumomab and atorvastatin calcium group(group A),the desutumomab group(group B),and the control group(group C)according to the drugs used,and the general data and laboratory examinations of the patients in the three groups were collected.General information and laboratory tests were collected from the three groups of patients,and basic information,bone metabolism,glucose metabolism,lipid metabolism,and myocardial injury indexes were compared among the three groups of patients.Results After 1 year of treatment,the alkaline phosphatase level of the three groups of patients decreased significantly compared with that before treatment(P<0.05),and the differences in lactate dehydrogenase(LDH)and fasting blood glucose levels of the three groups of patients after drug treatment were statistically significant(P<0.05),and compared with group C,the reduction of fasting blood glucose in group B was more significant,and the increase in LDH was more significant(P<0.05)after treatment.Comparison of creatine kinase(CK)level in group C and LDH level in group A before and after treatment within the group,the difference was statistically significant(P<0.05).Conclusion The effect of denosumab treatment on glucose metabolism in patients with POMP may be beneficial,and the use of denosumab may be a better choice for patients with diabetes combined with osteoporosis.The present study provides preliminary evidence that denosumab in combination with statin in patients with POMP resulted in lower LDH levels,whereas CK was elevated in patients treated with atorvastatin only,suggesting that denosumab may be more advantageous in regulating glucose metabolism,lipid metabolism,and the prevention of cardiovascular events.
